Intra-operative technology improves lumpectomy procedures for many breast cancer patients
the ONA take:
A recently developed, intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
These cancer cells are not typically visible during or after routine surgery. The MarginProbe system, manufactured and marketed by Dune Medical Devices, employs radio-frequency spectroscopy technology to detect cancer cells in the outer margins of removed tissue.
Dr. Freya Schnabel, Director of Breast Surgery at NYU Langone, led a multi-institutional retrospective study that evaluated nearly 600 patients that underwent lumpectomies for non-palpable breast malignancies. Dr. Schnabel utilized the new tool on approximately 50 patients, and the researchers concluded that the use of the MarginProbe system may as much as triple the odds of discovering additional cancer on removed tissue margins, when compared to more traditional intra-operative imaging.
In cases when cancerous cells are found in the margin tissue by the MarginProbe, the surgeon can remove additional tissue to be certain no cancer remains.
The use of this new tool could help surgeons determine that all cancer cells are excised during the initial surgery, sparing patients unnecessary additional procedures.
New intra-operative technology aids lumpectomy procedures by detecting microscopic amounts of cancer cells on tumor tissue.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|